Biocept, Inc.
BIOC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.07 | 0.01 | 0.00 |
| FCF Yield | -470.62% | 11.88% | -117.81% | -1,191.31% |
| EV / EBITDA | -0.07 | -0.68 | -1.00 | 0.21 |
| Quality | ||||
| ROIC | -117.56% | -5.03% | -41.21% | -164.31% |
| Gross Margin | -9.99% | 38.34% | 22.30% | -98.56% |
| Cash Conversion Ratio | 0.41 | -1.31 | 1.11 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.99% | 122.93% | 103.67% | 2.94% |
| Free Cash Flow Growth | -765.53% | 110.25% | 13.16% | -5.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | 6.72 | 0.14 | 0.29 |
| Interest Coverage | -101.21 | -8.31 | -6.61 | -11.08 |
| Efficiency | ||||
| Inventory Turnover | 37.57 | 14.25 | 11.06 | 14.29 |
| Cash Conversion Cycle | 20.53 | 37.74 | 77.92 | 191.50 |